Ironwood Pharmaceuticals executive resigns
IRWD Stock | USD 4.36 0.09 2.02% |
About 61% of Ironwood Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ironwood Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Ironwood Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Ironwood Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Ironwood |
Ironwood Pharmaceuticals executive resigns
Read at investing.com
Ironwood Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ironwood Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ironwood Pharmaceuticals Fundamental Analysis
We analyze Ironwood Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Ironwood Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Ironwood Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ironwood Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ironwood Pharmaceuticals Related Equities
NBIX | Neurocrine Biosciences | 0.29 | ||||
AMPH | Amphastar | 0.00 | ||||
AVDL | Avadel Pharmaceuticals | 0.66 | ||||
ITCI | Intracellular | 0.71 | ||||
ANIP | ANI Pharmaceuticals | 1.03 | ||||
COLL | Collegium Pharmaceutical | 1.72 | ||||
ALKS | Alkermes Plc | 2.03 | ||||
PCRX | Pacira BioSciences, | 2.60 | ||||
ASRT | Assertio Therapeutics | 3.65 | ||||
ESPR | Esperion Therapeutics | 5.26 |
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |